News
ORGO
--
0.00%
--
Antimicrobial Wound Dressing Market: Market Growth Factors, Applications, Regional Analysis, Key Players and Forecasts by 2027
Research Nester released a report titled which delivers detailed overview of the global antimicrobial wound dressing market in terms of market segmentation by product type, application, and by region.
AmericaNewsHour · 3d ago
Organogenesis Holdings Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q2, Organogenesis Holdings (NASDAQ:ORGO) earned $23.59 million, a 86.96% increase from the preceding quarter. Organogenesis Holdings also posted a total of $123.20 million in sales, a 20.13% increase since Q1.
Benzinga · 09/17 14:39
Advanced Wound Care Market: Business overview, Upcoming Trends and Top Company Analysis Forecast to 2028
Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2028"which delivers detailed overview of the global advanced wound care market in terms of market segmentation by product, by wound type, by end user and by region.
AmericaNewsHour · 09/14 09:40
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
CANTON, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgic...
GlobeNewswire · 09/10 13:00
Organogenesis Holdings (NASDAQ:ORGO) shareholders are still up 284% over 1 year despite pulling back 6.4% in the past week
Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality...
Simply Wall St. · 09/09 13:23
Forget Bargains, Play 5 Stocks with Rising P/E Instead
Zacks.com · 09/02 20:11
Can Organogenesis (ORGO) Run Higher on Rising Earnings Estimates?
Organogenesis (ORGO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks · 09/01 16:20
Deerfield Management Company, L.p. (series C) Buys Singular Genomics Systems Inc, CareMax Inc, ...
GuruFocus News · 08/24 19:38
Net Health Partners with Organogenesis for More Efficient Insurance Benefits Verification
Net Health, a leading provider of cloud-based software for specialty medical providers, announced today that Organogenesis Holdings Inc. (Nasdaq: ORGO), has become the first company to utilize Net Health® Wound Care's latest CTP Connections Module to elect...
PR Newswire · 08/23 11:00
Northwestern Mutual Investment Management Company, Buys Organogenesis Holdings Inc, Macerich ...
GuruFocus News · 08/16 16:38
Organogenesis Q2 Earnings Beat Expectations; Sales Jump 79%; Raises FY21 Sales Outlook
Benzinga · 08/10 21:31
Credit Suisse Maintains Outperform on Organogenesis Holdings, Raises Price Target to $25
Credit Suisse analyst Matt Miksic maintains Organogenesis Holdings (NASDAQ:ORGO) with a Outperform and raises the price target from $24 to $25.
Benzinga · 08/10 12:37
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 08/10 12:07
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9)
Benzinga · 08/10 11:55
Organogenesis (ORGO) Q2 Earnings and Revenues Beat Estimates
Organogenesis (ORGO) delivered earnings and revenue surprises of 114.29% and 16.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/09 21:25
BRIEF-Organogenesis Holdings Posts Q2 EPS Of $0.15
reuters.com · 08/09 20:50
Organogenesis Holdings: Q2 Earnings Insights
Shares of Organogenesis Holdings (NASDAQ:ORGO) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 400.00% year over year to $0.15, which beat the estimate of $0.07.
Benzinga · 08/09 20:39
Organogenesis Sees FY21 Revs $456M-$472M Vs $446.28M Est
For the twelve months ended December 31, 2021, the Company now expects: Net revenue of between $456 million and $472 million, representing an increase of
Benzinga · 08/09 20:05
Organogenesis Holdings Q2 EPS $0.15 Beats $0.07 Estimate, Sales $123.20M Beat $107.30M Estimate
Organogenesis Holdings (NASDAQ:ORGO) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.07 by 114.29 percent. This is a 400 percent increase over losses of $(0.05) per share
Benzinga · 08/09 20:04
Organogenesis Swings to Profit in Q2 As Revenue Jumps, Ups Revenue Guidance -- Stock Jumps 10% After-Hours
MT Newswires · 08/09 16:33
Webull provides a variety of real-time ORGO stock news. You can receive the latest news about Organogenesis Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About ORGO
Organogenesis Holdings Inc., formerly Avista Healthcare Public Acquisition Corp, is a regenerative medicine company. The Company focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. It also provides integrated healing solutions that substantially improve medical outcomes. The Company’s advanced wound care and surgical & sports medicine products include PuraPly, Antimicrobial (PuraPlyAM), PuraPly, Affinity, NuShield, Apligraf and Dermagraft. The Company is offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. The Company’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.